Read + Share
Huber H, Tausch E, Schneider C, Edenhofer S, et al. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax
for untreated CLL with del(17p)/TP53mut. Blood 2023;142:961-972.
PMID: 37363867
|
 |
|
Huber H, Tausch E, Schneider C, Edenhofer S, et al. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax
for untreated CLL with del(17p)/TP53mut. Blood 2023;142:961-972.
PMID: 37363867
|
|
|
|